New predictive model distinguishes indolent SM from advanced SM
A new model accurately distinguished between advanced and indolent systemic mastocytosis using blood sample parameters.
A new model accurately distinguished between advanced and indolent systemic mastocytosis using blood sample parameters.
Undiagnosed systemic mastocytosis (SM) led to bleeding complications in a patient with a peanut allergy reaction.
The study results challenge recommendations that people with systemic mastocytosis should avoid certain food and drugs entirely.
The woman lived with abdominal pain for more than a decade before receiving a diagnosis of indolent systemic mastocytosis.
Zoledronic acid, bisphosphonates, IFN-alpha and denosumab appear to prevent fractures and increase BMD in SM patients with osteoporosis.
Lipid-lowering medications (LLMs) may increase the risk of severe anaphylactic reactions, which would greatly affect patients with SM.
Indolent systemic mastocytosis (ISM) appears to significantly affect activities of daily living in over 50% of patients.
A new study detailed cellular and other changes resulting from avapritinib therapy for systemic mastocytosis.
The cellular marker CD30 appears to play a key role in cutaneous mastocytosis, which differs from systemic mastocytosis, a new study says.
Patients with mast cell activation syndrome (MCAS) could require annual controls to detect potential progression to systemic mastocytosis.